MedGenesis Partners with Pfizer to Develop GDNF Treatment and Delivery System for PD
MedGenesis Enters Into Agreement with Pfizer Inc. for Potential Treatments for Parkinson's Disease
MedGenesis Therapeutix Inc. ("MedGenesis"), a privately held biotechnology company focused on the development and precision delivery of definitive treatments for neurologic diseases, announced today that it has entered into an agreement with Pfizer Inc. ("Pfizer"), granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments for Parkinson's disease. Dr. Erich Mohr, Chief Executive Officer and Chairman of MedGenesis commented, "We believe that delivering drugs, including proteins, precisely to the regions of the brain where they are required will allow the potential for better treatments for a whole range of central nervous system (CNS) disease, and opens up the opportunity for the potential development of truly disease-modifying treatments of neurological diseases. We are delighted to be collaborating with Pfizer to complete our GDNF program, and we hope that this collaboration will result in potential treatments for people living with Parkinson's that could radically alter the course of their disease." MedGenesis is currently running a proof of concept study in Parkinson's disease with its aforementioned GDNF and CED technology. Under the terms of the agreement MedGenesis will receive an upfront option fee and upon exercise of the option by Pfizer will be eligible for further milestone and royalty payments. http://www.marketwatch.com/story/med...k=MW_news_stmp |
|
de-risking
Deals like this often don't disclose the terms (as is the case in this particular agreement). We are very excited as this is an example of a de-risking success -- meaning that strategic support over the last several years from MJFF (along with Cure Parkinson's Trust and Parkinson's UK) has advanced this program sufficiently to secure critical funds from a development partner.
There have been several other successes in the last weeks ... just what we are going for! Great news for the PD drug development pipeline. Debi |
Debi
I am crossing my fingers AND toes that this is av return of the good results we saw years ago.
Finally, someone is paying attention! God bless us all! Peggy |
Gdnf
It is interesting the UK clinical trial provides a delivery system with multiple infusions of the GDNF Protein, and the US method delivers the GDNF gene in a one time surgery.
I hope they are both successful , but it will be interesting to see which one is more effective. I can see pros and cons as a pwp -- for the uk delivery system you live with ports in your head and once established, i believe they plan for a once a month infusion of the GDNF a protein. The US method involves a one time brain surgery delivering GDNF genes via AAV. What if the Gdnf genes stop multiplying at some point? Of course I am assuming both will work. We will know with time. Jean Human participant #3 in the NIH GDNF GENE therapy trial, surgery date March7, 2014 |
Jeanb
Quote:
|
doing fine with no ill effects
Quote:
I think the Pfiser news is exciting!:eek: |
fwiw, GDNF article and possible VIT-D affect in vitro
http://www.plosone.org/article/info%...l.pone.0062040
was researching something else this morning and this popped up. |
Quote:
thanks for volunteering! http://clinicaltrials.gov/show/NCT01621581 |
Still recruiting
Quote:
You are followed for 5 years. Many many tests and trips to the NIH . It is a commitment! Remember phase I trials are for safety and not efficacy. They are also open label--everyone gets the treatment -- no one gets a placebo Jean |
All times are GMT -5. The time now is 06:16 AM. |
Powered by vBulletin Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.